ArticleJournal of clinical neurology (Seoul, Korea)2025
The Genetic Landscape of Acute Necrotizing Encephalopathy: Insights Into the Possible Pathogenesis.
Article in Journal of clinical neurology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tocilizumab as a key therapeutic option in high-risk pediatric acute necrotizing encephalopathy.Clinical and experimental pediatrics · 2026Article
- Article
- Pathogenesis and Research Models of Acute Influenza-Associated Encephalitis/Encephalopathy: An Update.Viruses · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
background and purposeAcute necrotizing encephalopathy (ANE) is a rare and severe type of parainfectious encephalopathy. The pathogenesis and genetic features of ANE remain underinvestigated. In this study we aimed to characterize the genetic profiles of ANE, including novel variants and pathways.
methodsWe conducted a retrospective cohort study of 16 ANE patients and 7 controls, collecting clinical data, cerebrospinal fluid (CSF) findings, neuroimaging findings, and treatment information. Whole-exome sequencing (WES) was performed to investigate potential function-impacting genetic mutations in
resultsThe median age of the ANE patients was 21 years, and viral infections such as SARS-CoV-2 and influenza were common triggers. The CSF interleukin-6 level was elevated in four patients (median=598 pg/mL, interquartile range=101-4,000 pg/mL). WES identified 278 low-frequency variants. Four pathogenic/likely pathogenic mutations (p.T585M and p.I656V) and one novel mutation of uncertain significance (p.P2733S) were identified in
conclusionsThis study integrated genetic profiles with the clinical characteristics of ANE patients, and revealed the role of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.